Anti-CGRP monoclonal antibodies in migraine: current perspectives
- 2.3k Downloads
Migraine is a highly disabling neurological pain disorder in which management is frequently problematic. Most abortive and preventative treatments employed are classically non-specific, and their efficacy and safety and tolerability are often unsatisfactory. Mechanism-based therapies are, therefore, needed. Calcitonin gene-related peptide (CGRP) is recognized as crucial in the pathophysiology of migraine, and new compounds that target the peptide have been increasingly explored in recent years. First tested were CGRP receptor antagonists; they proved effective in acute migraine treatment in several trials, but were discontinued due to liver toxicity in long-term administration. Monoclonal antibodies against CGRP (LY2951742, ALD-403, and LBR-101/TEV-48125) or its receptor (AMG334) were subsequently developed. As reviewed in this study, numerous phase 1 and 2 trials and preliminary results of phase 3 trials have shown a good safety/tolerability profile and efficacy in migraine prevention, especially in high frequent episodic and chronic forms. Being macromolecules, these mAbs are not suitable for oral administration; however, their intravenous or subcutaneous delivery can be performed at relatively low frequency—every month or even quarterly—which enhances patients’ compliance. Although not all migraineurs respond to this treatment, and longer administration periods will be needed to assess long-term effects, the results so far obtained are extraordinarily promising. The future introduction of mAbs on the market will probably represent a turning point for prevention similar to that represented by triptans for abortive treatment in migraine.
KeywordsMigraine CGRP Monoclonal antibodies against CGRP Migraine prophylaxis
Compliance with ethical standards
Conflict of interest
In the past 3 years: Maria Adele Giamberardino received research funding from Epitech Group, honoraria for participation in Advisory Board Meeting from Bayer, and participation in conferences from IBSA Institute Biochimique and Helsinn Healthcare, and Royalties from IASP Press. Giannapia Affaitati received honoraria for participation in conferences from Helsinn Healthcare and IBSA Institute Biochimique. Raffaele Costantini declares no conflict of interest. Martina Curto declares no conflict of interest. Andrea Negro received travel grants and participated to the Advisory Boards of Allergan, Electrocore and Medtronic. Paolo Martelletti received travel grants, honoraria consultancy and participated to in the Advisory Boards of Allergan, Bayer, Medtronic, Mylan and Teva.
Statement of human and animal rights
There is no need to cite/report any Ethical Statement.
This is an Invited review and no patients have been involved in this research study.
- 1.Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (published online June 8, 2015 at http://dx.doi.org/10.1016/S0140-6736(15)60692-4)
- 12.Mitsikostas DD, Rapoport AM (2015) New players in the preventive treatment of migraine. MC Med 13:279Google Scholar
- 30.Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B (2011) A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 12:361–368CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R, Lapenna D, Giamberardino MA (2009) A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 31(4):705–720CrossRefPubMedGoogle Scholar
- 35.Giamberardino MA, Affaitati G, Costantini R (2006) Chapter 24 referred pain from internal organs. Handb Clin Neurol 81:343–361Google Scholar
- 39.Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R (2016) Impact of migraine on fibromyalgia symptoms. J Headache Pain. doi: 10.1186/s10194-016-0619-8 (Epub 2016 Mar 22)
- 48.Durham PL (2006) Calcitonin gene-related peptide (CGRP) and migraine. Headache 46(Suppl 1):S3–S8Google Scholar
- 51.Cao T, Pinter E, Al Rashed S, Gerard N, Hoult JR, Brain SD (2000) Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol 164:5424–5429CrossRefPubMedGoogle Scholar
- 62.Marvizón JC, Pérez OA, Song B, Chen W, Bunnett NW, Grady EF, Todd AJ (2007) Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience 148:250–265CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Neal F, Arnold J, Rossant CJ, Podichetty S, Lowne D, Dobson C, Wilkinson T, Colley C, Howes R, Vaughan TJ (2016) Isolation of potent CGRP neutralizing antibodies using four simple assays. J Biomol Screen 21(1):24–34Google Scholar
- 81.Vermeersch S, Benschop RJ, Van Hecken A, Monteith D, Wroblewski VJ, Grayzel D, de Hoon J, Collins EC (2015) translational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model. J Pharmacol Exp Ther 354:350–357CrossRefPubMedGoogle Scholar
- 82.Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892CrossRefPubMedGoogle Scholar
- 83.Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107CrossRefPubMedGoogle Scholar
- 84.Goadsby PJ, Dodick DW, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2015) Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of frequent episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015Google Scholar
- 89.Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090CrossRefPubMedGoogle Scholar
- 90.Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100CrossRefPubMedGoogle Scholar
- 91.Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Sun H (2015) Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. In: 17th Congress of the International Headache Society, Valencia, 2015Google Scholar
- 92.Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390CrossRefPubMedGoogle Scholar
- 93.Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, Garcia CA, Pons J, Rosenthal A, Shelton DL (2008) CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 155:1093–1103CrossRefPubMedPubMedCentralGoogle Scholar
- 97.Edvinsson L, Ekman R, Uddman R, Kingman TA, McCulloch J (1984) Calcitonin gene related peptide (CGRP)-containing perivascular fibres in brain vessels: Localization and its effects in vitro and in situ. In: Presented at INSERM Symposium no. 25: Regulatory Peptides in Digestive, Nervous and Endocrine Systems. CNRS, ParisGoogle Scholar